AUTEL
17.1.2023 12:58:40 CET | Business Wire | Press release
Autel is today announcing the launch of an innovative electric vehicle DC charger, the MaxiCharger DC Compact, providing up to 40kW of DC power for the U.S. version and 47kW of power for the European version. The MaxiCharger DC Compact comes with two charging cables, allowing two vehicles to charge simultaneously with dynamic power distribution.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230117005624/en/
The MaxiCharger DC Compact comes with options like a credit card reader and a pedestal. (Photo: Business Wire)
The MaxiCharger DC Compact is sleek and compact with a 21.5-inch LCD touchscreen for user-friendly interaction and advertising capability. It can be hung on a wall, placed on a pedestal, or set on wheels for ultimate portability. The MaxiCharger DC Compact is perfect for businesses wanting to provide their customers with a quick top-up charge option without breaking the bank on a DC Fast charger. It is also an excellent option for commercial fleets that need a slower DC charge for their fleet vehicles to charge overnight.
“This is an exciting launch for Autel as we establish ourselves as the worldwide leader in electric vehicle charging,” said Kelvin Cao, Vice President of Global Marketing at Autel. “The MaxiCharger DC Compact is small in size but a powerful addition to our growing portfolio of EV chargers, and a great fit for businesses needing an affordable, yet fast EV charger.”
Elevated Efficiency with Dual Ports
The MaxiCharger DC Compact is designed to increase charging efficiency, providing up to 47kW of power with dual-ports. It can charge 2 vehicles simultaneously, sharing power dynamically between the two vehicles. A 30 minute charge equates to about 130 km of range, saving on charging time.
Smart Advertising and Communication Platform
Powered by the smart operating system, Android 10, with a user-friendly 21.5-inch LCD touchscreen and enhanced advertising placement capability, the MaxiCharger DC Compact communicates with, engages and attracts customers, generating new revenue streams.
Compatibility
The MaxiCharger DC Compact is OCPP1.6 capable. It is compatible with CCS1, CCS2 and CHAdeMO charging cables, depending on operator and regional needs. With the Autel Charge app, RFID cards, and credit card capability, the MaxiCharger DC Compact offers convenient ways for end users to pay for and begin their charging sessions. It offers 4G, Wi-Fi, and ethernet connectivity options and supports regular over-the-air software updates with an internet connection.
Cloud Platform
The MaxiCharger DC Compact is powered on the backend using Autel’s smart charge cloud platform. The cloud platform helps charge point operators view, monitor, and analyze charger data in real-time. Operators can also view revenue and user data, and set advertisements all from the cloud platform. Autel’s cloud management platform allows all operators to efficiently and conveniently manage their chargers in one easy-to-use interface.
Become a Dealer
If you are interested in becoming a dealer for the MaxiCharger DC Compact and for all of the MaxiCharger series of EV chargers, head over to the Autel website and fill out our dealer form. If you are interested in purchasing a MaxiCharger DC Compact, contact your local Autel sales representative or contact us below.
About Autel
Autel designs, engineers, and manufactures some of the most advanced products for residential and commercial users, offering hardware, software, apps, and cloud-based solutions to cover almost every use case and application.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230117005624/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom